With an upcoming earnings report, Apotex Health Corp is in the spotlight as investors speculate on its performance amidst recent strategic developments.
Apotex Health Corp (APTX.TO) is set to report its earnings for the first quarter of Fiscal 2027 on August 12, 2026. Investors are closely watching this release as the pharmaceutical company navigates a landscape marked by significant strategic moves and a rising EPS consensus. Analysts currently expect the company to report an earnings per share (EPS) of $0.51, reflecting a recent increase from earlier estimates.
Recent earnings trend
Advertisement
Apotex Health Corp
APTX.TO
APTX.TO
Apotex Health Corp
WealthAwesomeAdvertisement
Market cap
$8.66B
P/E
22.8x
52W high
$40.18
52W low
$26.05
1W change
+1.61%
Analyst Price Targets
Based on analyst covering APTX
Wall Street analysts forecast APTX stock price to rise 10.9% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$41.24
+10.9% Upside
Current Price
C$37.19
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APTX's historical volatility
30-Day Vol
53.9%
Annualized
90-Day Vol
51.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$44.46
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$39.47 | C$32.77 – C$47.54 |
| 60 trading days | C$41.89 | C$32.20 – C$54.50 |
| 90 trading days | C$44.46 | C$32.21 – C$61.37 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 9 analyst(s) cover this name; upcoming EPS consensus is available.
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-12 | — | 0.5100 | — |
Investor takeaway: With a moderately bullish consensus rating and a recent uptick in EPS estimates, Apotex Health Corp could be on the verge of a positive earnings surprise. However, investors should remain cautious given the lack of historical beat data.
Advertisement
EPS Estimate: $0.51
The EPS consensus has risen from $0.49 to $0.51 in the past month, indicating growing analyst confidence in Apotex's financial performance.
Bull case
The company's recent achievements, including Health Canada's approval for SEVMIA™ and a successful IPO, could strengthen its financial performance, potentially leading to better-than-expected earnings.
Bear case
Despite these positive developments, the lack of historical earnings beats raises concerns about the company's ability to meet or exceed expectations in this upcoming report.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
